Themis Medicare Ltd Technical Momentum Shifts Amid Mixed Market Signals

Technical Trend Overview and Price Movement

The stock closed at ₹117.10, down from the previous close of ₹118.40, with intraday highs and lows of ₹121.00 and ₹115.00 respectively. This places Themis Medicare comfortably above its 52-week low of ₹65.00 but still significantly below its 52-week high of ₹147.99. The recent technical trend has softened from a clear bullish stance to a mildly bullish one, signalling a potential consolidation phase or a pause in upward momentum.

Daily moving averages remain bullish, suggesting that short-term price momentum is still positive. However, weekly and monthly indicators show a more tempered outlook, with some oscillators and volume-based metrics indicating caution.

MACD and RSI Signals

The Moving Average Convergence Divergence (MACD) indicator remains bullish on the weekly chart, signalling that momentum is still favouring upward price movement in the near term. On the monthly chart, MACD is mildly bullish, indicating a slower but steady positive trend over a longer horizon. This divergence between weekly and monthly MACD readings suggests that while short-term traders may find opportunities, longer-term investors should remain vigilant.

Relative Strength Index (RSI) readings on both weekly and monthly charts currently show no clear signal, hovering in neutral zones. This absence of overbought or oversold conditions implies that the stock is not experiencing extreme price pressures, which could mean a period of sideways movement or gradual trend development.

Bollinger Bands and Moving Averages

Bollinger Bands on both weekly and monthly timeframes are mildly bullish, indicating that price volatility is contained within a range that favours upward movement. The bands suggest that the stock is not currently stretched to extremes, which could provide a stable base for further gains if buying interest returns.

Daily moving averages reinforce this view, with the stock price trading above key averages, supporting the notion of a short-term bullish bias. This alignment of moving averages often acts as a support level, reducing downside risk in the immediate term.

Volume and Trend Confirmation Indicators

On-Balance Volume (OBV) presents a mixed scenario: mildly bearish on the weekly chart but bullish on the monthly chart. This divergence suggests that while recent weekly trading volumes may be weak or selling-driven, the longer-term accumulation trend remains positive. Investors should watch for volume confirmation to validate any price moves.

The Know Sure Thing (KST) indicator is mildly bearish on the weekly timeframe but mildly bullish monthly, echoing the mixed signals seen in other metrics. Similarly, Dow Theory assessments reflect a mildly bearish weekly outlook contrasted with a mildly bullish monthly perspective, reinforcing the notion of short-term caution amid longer-term optimism.

Comparative Returns and Market Context

Examining Themis Medicare’s returns relative to the Sensex reveals a complex performance picture. Over the past week, the stock has declined by 6.17%, significantly underperforming the Sensex’s modest 0.54% drop. However, over the past month, Themis Medicare’s loss of 1.72% is less severe than the Sensex’s 4.84% decline, indicating some resilience.

Year-to-date, the stock has delivered a robust 16.34% return, outperforming the Sensex’s negative 13.29% return, a notable achievement for a micro-cap pharmaceutical company. Conversely, over the past year, Themis Medicare has underperformed with a 17.76% decline compared to the Sensex’s 8.95% fall. Longer-term returns over three and five years show underperformance relative to the Sensex, with a 33.51% loss over three years versus an 11.92% gain for the benchmark, and a 15.94% gain over five years against the Sensex’s 23.06%.

Over a decade, however, Themis Medicare has delivered a strong 101.17% return, though still trailing the Sensex’s 157.76% gain, reflecting the challenges and volatility inherent in the Pharmaceuticals & Biotechnology sector.

Mojo Score and Rating Update

The company’s MarketsMOJO score currently stands at 38.0, with a Mojo Grade of Sell, upgraded from a previous Strong Sell rating on 07 Sep 2026. This upgrade reflects some improvement in technical and fundamental factors but still signals caution for investors. The micro-cap status of Themis Medicare adds an additional layer of risk, given the typically higher volatility and lower liquidity associated with smaller market capitalisations.

Investor Takeaway and Outlook

Themis Medicare’s technical indicators suggest a stock at a crossroads. The mildly bullish monthly signals and daily moving averages offer some encouragement for a potential recovery or consolidation phase. However, the weekly bearish signals from volume and trend indicators counsel caution in the short term.

Investors should closely monitor volume trends and key support levels near current prices, especially given the stock’s proximity to its recent lows and the broader sector volatility. The absence of strong RSI signals implies that the stock is not currently overextended, which could provide a platform for renewed momentum if positive catalysts emerge.

Given the mixed technical signals and the company’s micro-cap status, a cautious approach is advisable. Long-term investors may find value in the stock’s attractive year-to-date performance and potential for recovery, but short-term traders should be wary of volatility and confirm trend direction before committing.

Overall, Themis Medicare remains a stock to watch closely, with technical momentum showing tentative improvement but still tempered by conflicting signals across multiple timeframes.

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →